GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amplia Therapeutics ATX.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.08

-7.87%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Amplia Therapeutics

Its shares trade on ASX under the ticker ATX.AX. It has been listed since 23 December 2013. In the fiscal year to 31 March 2025, it reported revenue of A$3.8m and a net loss of A$6.6m. At that date it held total assets of A$22.9m and shareholders' equity of A$21.0m.

Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The firm is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3).

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 Dec 2013
Employees
1

Leadership

Pay as last reported

  • Mr. Warwick TongNon-Executive Independent Chairman of the Board, since 2018A$33,000
  • Dr. Christopher BurnsChief Executive Officer, Managing Director, Director, since 2018A$22,000
  • Mr. Hamish GeorgeChief Financial Officer
  • Dr. Mark DevlinChief Scientific Officer
  • Dr. Jason LickliterChief Medical Officer
  • Mr. Andrew CookeCompany Secretary, since 2013
  • Mrs. Jane BellNon-Executive Independent DirectorA$22,000
  • Dr. Robert PeachNon-Executive Independent DirectorA$31,650

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.